Document Detail


Effects of an HMG-CoA reductase inhibitor in combination with an ACE inhibitor or angiotensin II type 1 receptor antagonist on myocardial metabolism in ischemic rabbit hearts.
MedLine Citation:
PMID:  12047036     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We investigated the effects of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, pravastatin, an angiotensin converting enzyme (ACE) inhibitor, temocaprilat, and an angiotensin II type 1 (AT1) receptor antagonist, CV-11974, on myocardial metabolism during ischemia in isolated rabbit hearts using phosphorus 31-nuclear magnetic resonance (31P-NMR) imaging. Forty-five minutes of continuous normothermic global ischemia was carried out. Pravastatin, temocaprilat, CV-11974 or a nitric oxide synthase inhibitor, L-NAME was administered from 60 min prior to the global ischemia. Japanese white rabbits were divided into the following experimental groups, a control group (n=7), a group treated with pravastatin (P group; n=7), a group treated with pravastatin and temocaprilat (P+T group; n=7), a group treated with pravastatin and CV-11974 (P+CV group; n=7), and a group treated with pravastatin and L-NAME (P+L-NAME group; n=7). During ischemia, P group, as well as either P+T group or P+CV group, showed a significant inhibition of the decreases in adenosine triphosphate (ATP) and intracellular pH (pHi) (p<0.01, respectively, at the end of ischemia compared to the control group as well as P+L-NAME group), and a significant inhibition of the increase in inorganic phosphate (Pi) (p<0.01, respectively, compared with the control group as well as P+L-NAME group). These results suggest that pravastatin significantly improved myocardial energy metabolism during myocardial ischemia. This beneficial effect was dependent on NO synthase. However, this beneficial effect was not enhanced by either temocaprilat or CV-11974.
Authors:
Hitoshi Kawabata; Kizuku Nakagawa; Kinji Ishikawa
Related Documents :
24358136 - Myocardial scar identified by magnetic resonance imaging can predict left ventricular f...
9420696 - Investigation of myocardial metabolism for the study of the pathophysiology of cardiac ...
1986156 - Studies of myocardial protection in the immature heart. iii. models of ischemic and hyp...
23273746 - Ecg-based signal analysis technologies for evaluating patients with acute coronary synd...
6778166 - Percutaneous transluminal angioplasty: general principles.
24819056 - Regional heterogeneity in cardiac sympathetic innervation in acute myocardial infarctio...
Publication Detail:
Type:  In Vitro; Journal Article    
Journal Detail:
Title:  Hypertension research : official journal of the Japanese Society of Hypertension     Volume:  25     ISSN:  0916-9636     ISO Abbreviation:  Hypertens. Res.     Publication Date:  2002 Mar 
Date Detail:
Created Date:  2002-06-05     Completed Date:  2002-11-13     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  9307690     Medline TA:  Hypertens Res     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  203-10     Citation Subset:  IM    
Affiliation:
First Department of Internal Medicine, Kinki University School of Medicine, Osakasayama, Japan. int1@med.kindai.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenosine Triphosphate / metabolism
Angiotensin Receptor Antagonists*
Angiotensin-Converting Enzyme Inhibitors / pharmacology*
Animals
Antihypertensive Agents / pharmacology
Benzimidazoles / pharmacology
Cardiotonic Agents / pharmacology
Drug Combinations
Enzyme Inhibitors / pharmacology
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
Myocardial Ischemia / metabolism*
Myocardium / metabolism*
NG-Nitroarginine Methyl Ester / pharmacology
Phosphates / metabolism
Pravastatin / pharmacology
Rabbits
Receptor, Angiotensin, Type 1
Tetrazoles / pharmacology
Thiazepines / pharmacology
Chemical
Reg. No./Substance:
0/Angiotensin Receptor Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Benzimidazoles; 0/Cardiotonic Agents; 0/Drug Combinations; 0/Enzyme Inhibitors; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Phosphates; 0/Receptor, Angiotensin, Type 1; 0/Tetrazoles; 0/Thiazepines; 110221-53-9/temocaprilat; 50903-99-6/NG-Nitroarginine Methyl Ester; 56-65-5/Adenosine Triphosphate; 81093-37-0/Pravastatin; S8Q36MD2XX/candesartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Impaired endothelial alpha-2 adrenergic receptor-mediated vascular relaxation in the fructose-fed ra...
Next Document:  Betaxolol inhibits extracellular signal-regulated kinase and P70S6 kinase activities and gene expres...